Immuno-Oncology Therapy: The Power of Syngeneic Tumor Models
Leading the Charge in Immunotherapy Research & Discovery
In the transformative landscape of immuno-oncology, syngeneic mouse models have emerged as invaluable tools, allowing researchers to simulate and assess the dynamics of immunotherapies within an intact, fully functional immune environment. By grafting mouse tumor cell lines into genetically identical mouse strains, we maintain a responsive immune system.
TD2’s specialized syngeneic models stand out with:
- Comprehensive Characterization – Dive deep into gene expression, TIL baseline populations, and the intricate dance with leading immune checkpoint inhibitors.
- Consistent Microbial Landscape — With advanced 16S rRNA gene sequencing initiated pre-study, we ensure a consistent microbiome, guaranteeing your research is conducted within a known and unchanging host environment.
- Effector Cell Profiling — Through the precision of multi-parameter flow cytometry, we decode the changes in immune cell phenotypes post-treatment, setting the stage for more effective and tailored immuno-oncology therapy advancements.
Learn more about our syngeneic services.
Contact our experts to help advance your immunotherapy candidate with our trusted preclinical research services.
E0771 Murine Breast Tumor Model
MC38 Murine Colon Tumor Model
CT-26 Murine Colon Tumor Model
IMMUNO-ONCOLOGY
Comprehensive preclinical services for immuno-oncology.
TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.
Large panel of human and murine tumor models
- 8 years of experience in cell therapy
- Expertise includes: CAR-T, NK-CAR, IPS-NKs, Macrophages
Humanized mice
- Human PBMCs or effector cell engraftment
- Sourced CD34+ humanized mice
- Humanized immune checkpoint inhibitor mice
